Table 1.
Participant characteristics for Omicron breakthrough infections.
| n | 12 |
|---|---|
| Gender (M/F) | 6 (50%), 6 (50%) |
| Age (Range) | 50.5 (30–78) |
| Race White Black/African American Other |
10 (83.3%) 1 (8.3%) 1 (8.3%) |
| Ethnicity Hispanic Not Hispanic |
4 (33.3%) 8 (66.6%) |
| COVID-19 Status at Study Entry Positive Negative |
6 (50%) 6 (50%) |
| Vaccine Manufacturer (Dose 1 + 2) n Pfizer/BioNTech BNT162b2 Moderna mRNA-1273 Johnson & Johnson Ad26.COV2.S |
12 (100%) 8 (66.7%) 3 (25%) 1 (8.3%) |
| Median Days Since 2nd Dose to Breakthrough (Range)1 | 172 (90–357) |
| Vaccine Manufacturer (Dose 3) n Pfizer/BioNTech BNT162b2/ Moderna mRNA-12732 |
7 (58.3%) 2 (28.6%) 5 (71.4%) |
| Median Days from 3rd Dose to Breakthrough (Range)3 | 61 (47–148) |
| Median Days from Pre-Breakthrough Sample Collection to Breakthrough (Range) | 31.5 (11–86) |
| Symptomatic Breakthrough | 11 (91.7%) |
1
Individuals with breakthrough infection following Dose 3 were not included.
2
Three individuals received half dose boosters (i.e., 50 mcg booster dose vs. 100 mcg for primary doses).
3
Individuals with breakthrough infection following Dose 2 were not included.